

Sanjay Swaminathan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150909/publications.pdf>

Version: 2024-02-01

42
papers

1,132
citations

394421

19
h-index

395702

33
g-index

42
all docs

42
docs citations

42
times ranked

1830
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression. <i>Journal of Immunology</i> , 2012, 188, 6238-6246.	0.8	152
2	Role of miR-155 in the regulation of lymphocyte immune function and disease. <i>Immunology</i> , 2014, 142, 32-38.	4.4	143
3	Hypermobility and sports injuries in junior netball players. <i>British Journal of Sports Medicine</i> , 2005, 39, 628-631.	6.7	98
4	Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 202-204.	1.2	92
5	The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection. <i>European Journal of Immunology</i> , 2013, 43, 510-520.	2.9	48
6	Interleukin-27 Is a Potent Inhibitor of cis HIV-1 Replication in Monocyte-Derived Dendritic Cells via a Type I Interferon-Independent Pathway. <i>PLoS ONE</i> , 2013, 8, e59194.	2.5	47
7	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. <i>RNA Biology</i> , 2011, 8, 1035-1046.	3.1	45
8	Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. <i>Biochemical and Biophysical Research Communications</i> , 2013, 434, 228-234.	2.1	43
9	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0167091.	2.5	38
10	miRNAs and HIV: unforeseen determinants of host-pathogen interaction. <i>Immunological Reviews</i> , 2013, 254, 265-280.	6.0	37
11	Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. <i>Genome Medicine</i> , 2019, 11, 26.	8.2	37
12	The role of microRNAs in HIV-1 pathogenesis and therapy. <i>Aids</i> , 2012, 26, 1325-1334.	2.2	34
13	Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 571-577.	7.2	28
14	Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. <i>Internal Medicine Journal</i> , 2014, 44, 694-696.	0.8	25
15	The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis. <i>Scientific Reports</i> , 2020, 10, 193.	3.3	24
16	Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection?. <i>Blood</i> , 2009, 113, 5029-5030.	1.4	22
17	Prevalence of sicca symptoms in a South Australian cohort with systemic sclerosis. <i>Internal Medicine Journal</i> , 2008, 38, 897-903.	0.8	21
18	miR-155 is differentially expressed in Treg subsets, which may explain expression level differences of miR-155 in HIV-1 infected patients. <i>Blood</i> , 2012, 119, 6396-6397.	1.4	21

#	ARTICLE	IF	CITATIONS
19	The Interaction of Human and Epstein-Barr Virus miRNAs with Multiple Sclerosis Risk Loci. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2927.	4.1	21
20	MicroRNA modulation of key targets associated with T cell exhaustion in HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 464-471.	3.8	19
21	The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. <i>EBioMedicine</i> , 2021, 71, 103572.	6.1	19
22	Gastric Cancer Screening in Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018, 38, 768-777.	3.8	18
23	Wheat flour immunotherapy in Baker's asthma. <i>Internal Medicine Journal</i> , 2007, 37, 663-664.	0.8	16
24	Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e98989.	2.5	14
25	Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2022, 127, 102781.	6.5	12
26	Comparison of two extractable nuclear antigen testing algorithms: ALBIA versus ELISA/line immunoassay. <i>Pathology</i> , 2016, 48, 491-497.	0.6	9
27	Gender and the Sex Hormone Estradiol Affect Multiple Sclerosis Risk Gene Expression in Epstein-Barr Virus-Infected B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 732694.	4.8	9
28	Emergence of de novo cutaneous vasculitis post coronavirus disease (COVID-19) vaccination. <i>Clinical Rheumatology</i> , 2022, 41, 1611-1612.	2.2	9
29	Sulfonamide crystals and acute renal failure. <i>Internal Medicine Journal</i> , 2006, 36, 399-400.	0.8	7
30	HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls. <i>Journal of AIDS & Clinical Research</i> , 2014, 05, .	0.5	5
31	Acute cytomegalovirus infection presenting with severe vulvar swelling. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 99, 133-134.	2.3	4
32	Prominent subcutaneous oedema as a masquerading symptom of an underlying inflammatory myopathy. <i>Internal Medicine Journal</i> , 2017, 47, 217-221.	0.8	4
33	Transcribed B lymphocyte genes and multiple sclerosis risk genes are underrepresented in Epstein-Barr Virus hypomethylated regions. <i>Genes and Immunity</i> , 2020, 21, 91-99.	4.1	4
34	ANCA-Associated Vasculitis in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3350-3354.	2.3	3
35	Formation of the Australian and New Zealand Vasculitis Society (ANZVASC) to improve the care of patients with vasculitis in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2020, 50, 781-783.	0.8	3
36	RNA duplexes in transcriptional regulation. <i>Biomolecular Concepts</i> , 2010, 1, 285-296.	2.2	1

#	ARTICLE	IF	CITATIONS
37	Author reply. Internal Medicine Journal, 2015, 45, 234-235.	0.8	0
38	Comparison of two ENA testing algorithms – ALBIA vs elisa/line immunoassay. Pathology, 2016, 48, S102.	0.6	0
39	258 – NK gene signature in SLE. , 2019, , .		0
40	262 – Immunological pathways in systemic lupus erythematosus disease manifestaion: cerebral lupus. , 2019, , .		0
41	Restricted migration of polyclonal IgG on immunofixation gel electrophoresis in a case of IgG4-related disease. Pathology, 2021, , .	0.6	0
42	FRI0011 – DEVELOPMENT OF A HIGH-DIMENSIONAL FLOW CYTOMETRY PANEL TO ANALYSE NATURAL KILLER CELLS IN SLE. Annals of the Rheumatic Diseases, 2020, 79, 576.2-576.	0.9	0